Reactions 1704, p301 - 2 Jun 2018 Haemoptysis: case report A 64-year-old man died of massive haemoptysis during treatment with pembrolizumab for stage-IVb lung adenocarcinoma [route not stated]. The man was scheduled to receive treatment with pembrolizumab 200mg every 21 days. rd On 3 November, the first dose of pembrolizumab was administered without any immediate side effects. His social history was significant for smoking and had no previous episodes of haemoptysis. On day 15, he developed massive haemoptysis and died. Author comment: "As the tumor was NSCLC strongly positive PD-L1, firstline pembrolizumab, a 200-mg flat dose every 21 days, was scheduled . . . The achievement of a great response and shrinkage in centrally located lung tumors with vascular involvement may be not so uncommon in strongly PDL1–positive NSCLC when pembrolizumab is used in the first-line setting. Therefore, the risk for severe bleeding may be a real concern." Artal-Cortes A, et al. Massive Hemoptysis after the First Administration of Pembrolizumab in a Strongly Positive, Centrally Located NSCLC. Journal of Thoracic Oncology 13: e76-e77, No. 5, May 2018. Available from: URL: http:// doi.org/10.1016/j.jtho.2017.12.004 - Spain 803323731 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera